The objective of this grant is to determine whether the intrarenal renin angiotensin system modulates the hyperplastic growth of the tubular epithelium and the process of cystogenesis in autosomal dominant polycystic kidney disease (ADPKD). The general hypothesis is that the renin angiotensin system is an important component of the complex network of peptide growth factors and hormones that control tubular epithelial cell proliferation and its blood supply in ADPKD. In preliminary studies, we have demonstrated the association of hypertension and ADPKD, the adverse effect of hypertension on kidney survival in this disease, the central role of the renin angiotensin system in the pathogenesis of this hypertension, the correlation between the severity of cystic disease and the activation of the renin angiotensin system in a chemically induced experimental model, the presence of renin in the tubular epithelial cells and cyst fluids, and the synthesis of renin by cyst derived, cultured epithelial cells. For the proposed studies, we will use a new rat mutant with ADPKD, as well as tubular epithelial cell cultures derived from these rats and from human polycystic kidneys. We will determine (1) whether the blockade of the renin angiotensin system inhibits cystogenesis in ADPKD, (2) whether genetically determined increased expression of the renin gene enhances cystogenesis in this disease, (3) whether cultured epithelial cells derived from ADPKD kidneys, as compared to normal kidneys, have an increased capacity to synthesize renin, angiotensinogen, angiotensin converting enzyme, and peptide growth factors or are more sensitive to the growth promoting effects of angiotensin II and peptide growth factors, and (4) whether the presence and localization of renin, angiotensinogen, angiotensin converting enzyme, peptide growth factors, and receptors for angiotensin II and peptide growth factors are abnormal in ADPKD. The results of these studies will augment the understanding of the pathogenesis of cyst formation and hypertension in ADPKD and are likely to have a significant impact on the treatment of this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK044863-04
Application #
2144127
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1991-09-30
Project End
1995-08-31
Budget Start
1994-09-01
Budget End
1995-08-31
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Brosnahan, Godela M; Abebe, Kaleab Z; Moore, Charity G et al. (2018) Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis 71:666-676
Besse, Whitney; Choi, Jungmin; Ahram, Dina et al. (2018) A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat 39:378-382
Cornec-Le Gall, Emilie; Torres, Vicente E; Harris, Peter C (2018) Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 29:13-23
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier et al. (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33:477-489
Kline, Timothy L; Edwards, Marie E; Garg, Ishan et al. (2018) Quantitative MRI of kidneys in renal disease. Abdom Radiol (NY) 43:629-638
Cornec-Le Gall, Emilie; Blais, Jaime D; Irazabal, Maria V et al. (2017) Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant :
Perrone, Ronald D; Mouksassi, Mohamad-Samer; Romero, Klaus et al. (2017) A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 2:451-460
Holditch, Sara J; Schreiber, Claire A; Harris, Peter C et al. (2017) B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease. Kidney Int 92:657-668

Showing the most recent 10 out of 105 publications